- All shares issued to Boots Pure Drug Co. Ltd. Only 5 shares issuedfor cash.

1963

- 2 00 000 shares issued to the present Company.

1965

- The Company was incorporated on 15th December. The CompanyManufacture `Boots' brand of medical and pharmaceutical products andagricultural and animal health products. The leading lines ofmanufacture includes insulin injections anti-dysentery drugs vitaminpreparations penicillin preparations sulphonamide tablets householdremedies animal health products of Mindif series and agro-chemicals.

- The plant with a licensed capacity of 1 500 mega units per annum wascommissioned in January. In September a sterile manufacturing unitfor the vialling of insulin injections was commissioned.

- On 19th October the Company entered into a technical collaborationagreement with Boots Pure Drug Co. Ltd. England for manufacturingcrystalline insulin and formulations thereof and agreed to pay to themat the rate of 3% on the sale value of basic crystalline insulin usedin the manufacture of preparations thereof subject to a maximum of5 000 per annum.

- In December 2 00 000 shares issued to public (prem. Rs 13 pershares).

1969

- 25 000 shares issued at par to L.I.C. U.T.I. and I.C.I.C.I. onconversion of 5% debenture holdings.

1971

- The name of the Company was changed from Boots Pure Drug Co. (India)Ltd. to the present one from 1st November. The name was furtherchanged to Boots Pharmaceuticals Ltd. from 1st January.

1973

- 25 000 shares issued at par to L.I.C. U.T.I. and I.C.I.C.I. onconversion of 5% debenture holdings.

1976

- The Company undertook to set up a new chemical plant at Ahmednagar abackward area in Maharashtra for the manufacture of Ibuprofen from thebasic stage in technical collaboration with its parent company.Ibuprofen is a raw material of Boots original research.

- 7 75 000 Bonus shares issued in the proportion 1:1.

1977

- 1 48 150 Right Equity shares issued to Indian shareholders (prem. Rs3.50 per shares: prop. 2:9)

1979

- 2 66 050 Bonus shares issued in prop. 1:3.

1983

- The Company issued 1 70 000-15% non-convertible debentures of Rs 100each. These debentures were redeemed on 5th October 1990 at a premiumof Rs 5 per debenture.

- Boots Company PLC England voluntarily decided to dilute itsshareholding in the Company by disinvesting 3 00 000 equity share of Rs10 each at a premium of Rs 45 per share.

- The Company also issued 4 27 290 No. of Equity shares of Rs 10 eachat a premium of Rs 45 per share as rights to resident Indian equityshareholders.

- Out of the total issue of 7 27 280 No. of equity share 6 81 088shares were offered as rights to shareholders other than Boots CompanyPLC England in the proportion 2:5. Only 6 12 031 shares were takenup. Out of the remaining 46 192 shares 36 364 shares were offered toemployees Including Indian working directors)/workers on equitablebasis and 9 828 shares were offered to business associates of theCompany. The unsubscribed portion of 69 057 shares of theshareholder's quota were allotted to employees/workers of the Company.

- The object of rights issue and offer for sale was to reduce theholding of Boots Company PLC England in the Company from 53% to 40%.

1984

- 13 58 520 Bonus equity shares issued in prop. 3:5.

1986

- Applications were made to Government for expansion of capacity upto200 tonnes per annum for Ibuprofen and an endorsement of capacity upto300 M.U. for highly purified insulin.

- 4 27 280 new equity shares were offered as Rights to the residentIndian equity shareholders at a premium of Rs 45 per shares.

1987

- The Company received a letter of intent for both the products and theexpansion capacity of Ibuprofen was being implemented.

- An application was made for an industrial license to produce a bulkdrug "Ranitidine Hydrochloride" and its formulations.

- 40 50 000 bonus equity shares issued in prop. 1:1.

1988

- `Advene' a new anti-peptic ulcerant and `Froben' a more potentanti-rheumatic drug were launched.

- The Company undertook a project to set up a new formulation factoryat Jejuri in Pune district.

1989

- A number of new products namely Brufen Junior Syrup Chota StrepsilsIcy Optrex Eye Lotion Highly Purified Insulins and Nausidome werelaunched during the year.

1991

- A few new products like Human Insulin's Frozen SR. and Optren EyeDrops were launched during the year.

1994

- Products such as Novopen Human mixtard Mixtard penfills werelaunched.

- Beem Healthcare Ltd. Lenbrook Pharmaceuticals Ltd. and ValenciaPharmaceuticals Ltd are the subsidiaries of the Company.

1995

- It is proposed to change the name of the company to KnollPharceuticals Ltd. effective 31st October name was changed to KnollPharmaceuticals Ltd.

1997

- Clivarine an anticoagulant low molecular weight heparin preparationused for the prophylasix of deep vein thrombosis was launched.

- The Company has acquired the product Epilex for a total considerationof Rs 9.90 crores. The product is used in the treatment of epilepsy.

- The new Goa plant of Knoll Pharmaceuticals a part of the BASF group has been set up. BASF India has also set up two state-of-the-artplants to manufacture speciality dyes and dispersons in Mangalore andthese were commissioned.

- Knoll Pharma is currently the fifth-largest domestic formulationscompany. It is likely to use the proceeds to acquire formulationbrands in the cardiovascular antibiotic and neurology segments.

- Lupharma GmbH a wholly owned subsidiary of Knoll AG of Germany ismaking a public offer for the acquisition of a further 11 per centholding in Knoll Pharmaceuticals Ltd (KPL) the Indian arm of thebusiness.

- Knoll India has recently entered into a co-marketing arrangement withSmithKline Beecham Pharmaceuticals (India) for the latter's formulationof amoxycillin and clavulanic acid.

- Knoll India is to launch new products from the research pipelines ofboth Knoll AG and the erstwhile Boots plc.

1998

- KPL launched an anticoagulant low molecular weight heparinpreparation - Cremaffin - used for the prophylaxis of deep veinthrombosis.

- Lupharma GmbH a wholly-owned subsidiary of Knoll AG of Germany hadmade a public offer for acquisition of a further 11 per cent holding inKnoll Pharmaceuticals in order to take its stake up to 51 per cent fromthe current levels of 40 per cent.

1999

- Beem Healthcare which was engaged in marketing of consumer brands hasbeen merged with Knoll with effect with July 1998.

- Knoll Pharma has entered into a three-way pact with the Gujarat-basedTorrent Pharmaceuticals and Danish giant Novo Nordisk in theanti-diabetes (human insulin) segment.

2000

- The Company has entered into a agreement with Kalpataru Homes for theassignment of the leasehold.

- Ranbaxy Laboratories Ltd (RLL) has entered into an agreement withKnoll Pharmaceuticals Ltd (KPL) to market the latter's leading brandsin select overseas markets.

2001

- Lupharma UK Holding One Ltd. a wholly-owned subsidiary of LupharmaGmbH has proposed to acquire 82 62 000 shares i.e. 51 per cent of theshare capital of Knoll Pharmaceuticals from Lupharma Gmbh.

2002

-Knoll Pharmaceuticals the maker of popular painkiller Brufen has changed its name to Abbott India following global takeover of Knoll's majority stakeholder - German firm BASF Pharma - by US drug major Abbott Laboratories.

2003

-Mr V D Narkar Director of Abbott India Ltd has resigned with effect from June 19 2003.

-Mr.Ashok Dayal is appointed as Additional Director of the company.

-Scheme of amalgamation of Lenbrook Pharmaceuticals (a wholly owned subsidiary of the company) with the company.

2008